AVITA Medical, Inc. Form 8-K Summary
Filing date: March 22, 2021. The filing reports the appointment of Michael Holder as Chief Financial Officer and related employment and indemnification arrangements. It does not provide quarterly or annual financial results.
Business Context and Reporting Period
AVITA Medical is a Delaware corporation whose common stock trades on Nasdaq under the symbol RCEL. The report covers events effective March 22, 2021. Mr. Holder will oversee global finance, accounting, mergers and acquisitions, and investor relations from the Company’s Valencia, California office.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit or loss, cash flow, operating margin, debt, cash balance, liquidity, or other periodic financial metrics.
- No financial guidance or changes to the Company’s capital structure are disclosed.
Material Changes and Executive Compensation
- Michael Holder was appointed Chief Financial Officer effective March 22, 2021.
- His employment is at will and has no specified term.
- Annual base salary is $425,000, subject to annual Board review.
- He is eligible for an annual performance bonus equal to 40% of base salary, based on Company and individual performance. For 2021, eligibility is limited to 40% of his pro rata base salary earned during the year.
- The Board may award an additional amount of up to 50% of the annual performance bonus based on performance.
- Bonus eligibility requires continued employment and no resignation or termination notice when the bonus is determined and paid.
- He will receive a $30,000 grossed-up relocation payment and must relocate to the Valencia area under the conditions specified in the agreement; repayment is required if he fails to relocate within the stated period.
- Subject to Board approval, he is eligible for 150,000 options. Of these, 112,500 are tied to established performance metrics and 37,500 vest at 9,375 per year over four years, beginning after the first year of service.
- The Company entered into its standard form of indemnification agreement with Mr. Holder, covering specified expenses and liabilities to the extent permitted by law.
Outlook, Risks, Contingencies, and Unusual Items
- The appointment is intended to strengthen oversight of finance, accounting, M&A, and investor relations, but the filing provides no quantified operating or financial outlook.
- Potential compensation obligations include salary, performance bonuses, relocation costs, equity awards, and indemnification obligations.
- The equity awards remain subject to Board approval and the terms of the Company’s 2020 Omnibus Incentive Plan and related agreement.
- The filing includes no disclosed litigation, debt covenant issue, restructuring, impairment, or other unusual financial event.
Investor Verification Checklist
- Review Exhibit 10.1 for the complete employment agreement, including termination provisions and option terms.
- Verify whether the 150,000-option grant was approved and the applicable exercise price, vesting conditions, and accounting treatment.
- Assess the potential annual compensation cost, including the base salary, bonus opportunity, relocation payment, and equity compensation.
- Review subsequent filings for changes in CFO status, compensation, or the Company’s financial condition.
- Use the Company’s periodic reports—not this Form 8-K—for revenue, cash, debt, liquidity, margins, and operating guidance.